Factor H (FH) is an abundant serum glycoprotein that regulates the alternative pathway of
complement-preventing uncontrolled plasma C3 activation and nonspecific damage to host …

Atypical hemolytic uremic syndrome (aHUS) may be associated with mutations in the C-
terminal of factor H (FH). FH binds to platelets via the C-terminal as previously shown using …

The autoimmune form of atypical hemolytic uremic syndrome (HUS) is characterized by
circulating autoantibodies against the complement regulator factor H, and is often …

Atypical hemolytic uremic syndrome (aHUS) is a disease of hemolytic anemia,
thrombocytopenia, and renal failure associated with defective alternative pathway (AP) …

Factor H autoantibodies have been reported in approximately 10% of patients with atypical
hemolytic uremic syndrome (aHUS) and are associated with deficiency of factor H–related …

This study reports on six cases of deficiency in the human complement regulatory protein
Factor H (FH) in the context of an acute renal disease. Five of the cases were observed in …

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated
with mutations in complement proteins, most frequently in the main plasma alternative …

Complement factor H is a potent inhibitor of alternative pathway complement activation. The
factor H gene, a member of the regulators of complement activation (RCA) gene cluster …

Factor H (FH) is the key regulator of the alternative pathway of complement. The carboxyl‐
terminal domains 19–20 of FH interact with the major opsonin C3b, glycosaminoglycans …

Many of the complement regulatory genes within the RCA cluster (1q32) have arisen
through genomic duplication and the resulting high degree of sequence identity is likely to …